Optimizing IO/TKI Success: Managing Adverse Effects and Personalizing Treatment

EP: 1.Long-Term Outcomes in Advanced RCC: Analyzing 8 Years of CheckMate 214 Data

EP: 2.Optimizing IO-TKI Selection: Patient-Specific Approaches for Optimal Outcomes

EP: 3.Long-Term Data From CheckMate 9ER Investigating Nivolumab Plus Cabozantinib in Untreated Advanced RCC

EP: 4.RCC Treatment Selection: Expert Perspectives on Long-Term Data and Insights on Treatment Selection

Now Viewing

EP: 5.Optimizing IO/TKI Success: Managing Adverse Effects and Personalizing Treatment

EP: 6.Navigating RCC Progression: Optimizing Treatment Sequence After the First Line

EP: 7.Post-Immunotherapy Options in RCC: Latest Trial Data and Expert Perspectives on Rechallenge Strategies

EP: 8.Emerging Therapies in RCC: Shaping Future Treatment Sequences

EP: 9.RCC Treatment Evolution: Expert Perspectives on the Evolving Landscape and Advances From ASCO GU 2025

Video content above is prompted by the following:

• What regimens have you found to offer the most favorable toxicity profile? How do you personalize treatment to minimize patient burden?
• What are your preferred strategies for patients who have completed pembrolizumab in the adjuvant setting?
• How does the timing of recurrence relative to adjuvant therapy completion influence your treatment selection?
• Please discuss which patients might still be candidates for initial active surveillance. Which factors prompt you to consider active surveillance rather than immediate systemic therapy?